| Title : Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes - Jojima_2016_Diabetol.Metab.Syndr_8_45 |
| Author(s) : Jojima T , Tomotsune T , Iijima T , Akimoto K , Suzuki K , Aso Y |
| Ref : Diabetol Metab Syndr , 8 :45 , 2016 |
| Abstract : Jojima_2016_Diabetol.Metab.Syndr_8_45 |
| ESTHER : Jojima_2016_Diabetol.Metab.Syndr_8_45 |
| PubMedSearch : Jojima_2016_Diabetol.Metab.Syndr_8_45 |
| PubMedID: 27462372 |
Jojima T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso Y (2016)
Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
Diabetol Metab Syndr
8 :45
Jojima T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso Y (2016)
Diabetol Metab Syndr
8 :45